Celgene International Sárl (CELG) Release: Data Evaluating Combination Treatments Including REVLIMID® Plus Antibody Therapies in Patients With Various Difficult-to-Treat Forms of Non-Hodgkin Lymphoma Presented at the 54th American Society of Hematology Annual Meeting  
12/12/2012 9:30:25 AM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced results from several studies evaluating combination treatment with REVLIMID® (lenalidomide) and antibody therapy in non-Hodgkin lymphoma (NHL). The data were presented at the 54th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA. The presented data included two Phase II trials on the combination of lenalidomide with R-CHOP, a Phase I/II trial evaluating the combination of lenalidomide and ofatumumab, and a Phase II trial analyzing the combination of lenalidomide and rituximab. First, a Phase II trial (abstract #689) evaluated lenalidomide in combination with R-CHOP (rituximab-CHOP) in patients with aggressive B-cell lymphomas, including diffuse large B-cell lymphoma and follicular lymphoma. Treatment resulted in an overall response rate (ORR) of 98% and one-year progression-free survival (PFS) rate of 73%. Grade =3 hematological toxicities were thrombocytopenia (40%), neutropenia (89%), and anemia (19%). Non-hematological side effects of grade 3 or higher included febrile neutropenia (10%), pneumonia (4%), sepsis (2%), venous thrombosis (2%), fatigue (6%), and dehydration (6%).